BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.
BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.
Authors: Tobias Rausch; David T W Jones; Marc Zapatka; Adrian M Stütz; Thomas Zichner; Joachim Weischenfeldt; Natalie Jäger; Marc Remke; David Shih; Paul A Northcott; Elke Pfaff; Jelena Tica; Qi Wang; Luca Massimi; Hendrik Witt; Sebastian Bender; Sabrina Pleier; Huriye Cin; Cynthia Hawkins; Christian Beck; Andreas von Deimling; Volkmar Hans; Benedikt Brors; Roland Eils; Wolfram Scheurlen; Jonathon Blake; Vladimir Benes; Andreas E Kulozik; Olaf Witt; Dianna Martin; Cindy Zhang; Rinnat Porat; Diana M Merino; Jonathan Wasserman; Nada Jabado; Adam Fontebasso; Lars Bullinger; Frank G Rücker; Konstanze Döhner; Hartmut Döhner; Jan Koster; Jan J Molenaar; Rogier Versteeg; Marcel Kool; Uri Tabori; David Malkin; Andrey Korshunov; Michael D Taylor; Peter Lichter; Stefan M Pfister; Jan O Korbel Journal: Cell Date: 2012-01-20 Impact factor: 41.582
Authors: Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova Journal: Pathol Oncol Res Date: 2014-08-23 Impact factor: 3.201
Authors: Phuong L Mai; David Malkin; Judy E Garber; Joshua D Schiffman; Jeffrey N Weitzel; Louise C Strong; Oliver Wyss; Luana Locke; Von Means; Maria Isabel Achatz; Pierre Hainaut; Thierry Frebourg; D Gareth Evans; Eveline Bleiker; Andrea Patenaude; Katherine Schneider; Benjamin Wilfond; June A Peters; Paul M Hwang; James Ford; Uri Tabori; Simona Ognjanovic; Phillip A Dennis; Ingrid M Wentzensen; Mark H Greene; Joseph F Fraumeni; Sharon A Savage Journal: Cancer Genet Date: 2012-08-29
Authors: Rodrigo Santa Cruz Guindalini; Andrew Song; James D Fackenthal; Olufunmilayo I Olopade; Dezheng Huo Journal: Cancer Date: 2016-03-15 Impact factor: 6.860
Authors: Carla Pinto; Isabel Veiga; Manuela Pinheiro; Ana Peixoto; Armando Pinto; José M Lopes; Rui M Reis; Carla Oliveira; Manuela Baptista; Lúcia Roque; Fernando Regateiro; Luís Cirnes; Robert M W Hofstra; Raquel Seruca; Sérgio Castedo; Manuel R Teixeira Journal: Fam Cancer Date: 2009-05-26 Impact factor: 2.375
Authors: Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell Journal: Nat Rev Clin Oncol Date: 2014-03-18 Impact factor: 66.675
Authors: Nuria Seguí; Marta Pineda; Elisabet Guinó; Ester Borràs; Matilde Navarro; Fernando Bellido; Victor Moreno; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá; Laura Valle Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240